Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Infliximab (Remicade®) as an Adjunct to Pegylated- Interferon α-2b and Ribavirin in the Treatment of Hepatitis C Virus Infection

NCT00512278 is registered in ClinicalTrials.gov with Nizar Zein as lead sponsor.

NCT NCT00512278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00512278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Infliximab (Remicade®) as an Adjunct to Pegylated- Interferon α-2b and Ribavirin in the Treatment of Hepatitis C Virus Infection
Lead sponsor
Nizar Zein
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
May 31, 2012
Enrollment
146 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c